Areas of expertise
- Legal and compliance services
- Corporate/M&A
- Banking and finance
- Capital markets
- Comercial
- Antitrust/Competition
- Intellectual property
- Dispute resolution
- Private clients
- Real estate
- Due diligence services
- Operational due diligence
- Investment due diligence
- Auditing services
- Data rooms
- Fund services
- Upfront consulting
- Fund administration
- Custody
- Trading
- Regulatory & compliance services
- Fund governance
- Fund operations
- Country specific help
- Risk management/reporting
- Banking services
- Branch and retail services
- Financing
- Merger & Acquisitions
- Custodian services
- Underwriting
- Brokerage/Payment
- Insurance services
- Pension schemes
- General insurance policies
- Catastrophe insurance policies
- Insurance broker/advisory
- Life insurance policies
- Consulting for investing
- Market research
- Investment consulting/advisory
- Risk management consulting
- Benchmarking
- Capital introduction
- Sales & Marketing
- Communication
- Advertising
- Fintech
- Finance management
- Alternative financing
- ICT
- Software
- Hardware services
- Data services
- General services
- HR services
- Finance & accounting
- Real estate services
- Planning & building
- Property utillization
- Evaluation & financing
- Facility/property management
- Investment research
- Company research
- Sustainability
- Technical research
- Quantitative
- Asset class
- Other
- Thematic research
- Credit, rates & currencies
- Industry
- Health care
- Commodities
- Macro & politics
- Europe
- US
Served jurisdictions
Switzerland, Germany, France, United Kingdom, United States
Show more
We speak
English, Arabic
Website
The company will be in the pharmaceutical domain producing new vaccines, treatment components, and laboratory diagnostic kits. The company is established to help in fighting: 1. TB in humans and bovine by producing Erythra TB diagnostic kit which is simple but provides high sensitivity and specificity. 2. Cancers by producing early detection and monitoring diagnostic kits. 3. COVID-19 by producing a highly sensitive diagnostic kit for measuring the infection load, monitoring treatment, and identifying a complete cure. 4. Other kits for new viruses and infectious disorders can be developed very rapidly once identified. All company products will be highly efficient because they are developed based on a scientific approach based on the concrete understanding of biological processes related to the immune system. The company will control the industry on a monopoly basis. The market size is multi-billion / year, as the population suffering from those diseases is high. The risk will be political influences that can be played by large companies that may be affected.
About Functional Sourcing
Pages
Stay connected
Subscribe to our monthly newsletter
